Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation-Reference-Cited by-同舟云学术

Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation

Published:2014-10 Issue:5 Volume:28 Page:829-838
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Moreau Philippe,Hulin Cyrille,Facon Thierry

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference42 articles.

1. Seer cancer statistics review, 1975–2009 (vintage 2009 populations);Howlade,2012

2. Epidemiology of multiple myeloma;Beker;Recent Results Cancer Res,2011

3. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation;Palumbo;J Clin Oncol,2014

4. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials;J Clin Oncol,1998

5. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM99-06): a randomised trial;Facon;Lancet,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which therapies will move to the front line for multiple myeloma?;Expert Review of Hematology;2017-04-24

2. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial;Journal of Clinical Oncology;2016-10-20

3. Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma;RNA Biology;2015-09-23

4. Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation;Drugs & Aging;2015-04-30